CBIO - NASDAQ

Crescent Biopharma, Inc.

CBIO·NASDAQ

$17.95

+5.6%

HealthcareBiotechnology

Crescent Biopharma, Inc., an oncology company, develops therapies for cancer patients. Its pipeline includes a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates to treat solid tumors. The company is headquartered in Waltham, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$495.05M

EPS-14.7800

P/E Ratio-1.21

Earnings Date07/30/2026

240.29M

Assets

575%

3Y+364.0%

5Y+68.0%

10Y+467.0%

37.28M

Total Liabilities

-27%

3Y+320.0%

5Y+155.0%

10Y+426.0%

203.01M

Total Equity

-1412%

3Y+373.0%

5Y+58.0%

10Y+475.0%

Crescent Biopharma, Inc. Funding & Solvency Profile

CBIO · NASDAQ

Current Assets

Cash & Cash Equivalents213.19M

Net Receivables18.00M

Inventory0.00

Other Current Assets5.46M

Total Current Assets237 M

Non-Current Assets

Property, Plant & Equipment2.31M

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets1.32M

Total Non-Current Assets4 M

Total Assets

240.29M

Financial Health Analysis

Current Ratio

6.56x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.18x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

201 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

98% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Crescent Biopharma, Inc. Balance Sheet

CBIO • NASDAQ

Crescent Biopharma, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	213.2M	34.8M	41.8M	47.9M	90.3M	137M	158.2M	209.9M	123.9M	40M	46.8M	55.2M	2.3M	17.4M	28.2M
Short-Term Investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.6K	9.3K	16.3K	1K	0.0	0.0
Cash & Short-Term Investments	213.2M	34.8M	41.8M	47.9M	90.3M	137M	158.2M	209.9M	123.9M	40M	46.8M	55.2M	2.3M	17.4M	28.2M
Net Receivables	18M	0.0	175.8K	144K	1.3K	2.1K	186K	413.1K	102K	268.7K	38.7K	22.3K	94.8K	0.0	0.0
Accounts Receivables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	102K	268.7K	38.7K	0.0	0.0	0.0	0.0
Other Receivables	18M	0.0	175.8K	144K	1.3K	2.1K	186K	413.1K	0.0	0.0	0.0	22.3K	94.8K	0.0	0.0
Inventory	0.0	0.0	0.0	0.0	0.0	0.0	441.0	-405.0	0.0	198.8K	393.4K	-77.0	0.0	0.0	0.0
Prepaids	0.0	0.0	1.8M	2.7M	532.5K	1.2M	4.1M	1.9M	3.2M	209.8K	403.1K	836.2K	171.8K	596.2K	194.2K
Other Current Assets	5.5M	38K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	16.3K	2.3M	0.0	0.0
Total Current Assets	236.7M	34.8M	43.8M	50.7M	90.8M	138.3M	162.5M	212.3M	127.2M	40.5M	47.2M	56.1M	4.9M	18M	28.4M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	2.3M	0.0	767.8K	751.2K	1.9M	2.9M	3.8M	957.2K	1.1M	1.1M	521.4K	452.3K	399.8K	450.8K	234.5K
Other Non-Current Assets	1.3M	813K	757.9K	344.7K	1.6M	1.6M	1.6M	1.6M	256.7K	811.9K	696.5K	696.5K	0.0	-450.8K	308.5K
Total Non-Current Assets	3.6M	813K	1.5M	1.1M	3.6M	4.6M	5.4M	2.6M	1.4M	1.9M	1.2M	1.1M	399.8K	450.8K	543K
Other Assets	0.0	0.0	0.0	0.0	0.0	0.0	321.0	-272.0	0.0	-327.0	-279.0	27.0	0.0	0.0	0.0
Total Assets	240.3M	35.6M	45.3M	51.8M	94.3M	142.8M	168M	214.8M	128.6M	42.4M	48.5M	57.3M	5.3M	18.4M	28.9M
LIABILITIES
CURRENT LIABILITIES
Total Payables	10M	7.3M	868.1K	970.2K	2.1M	2.1M	1.4M	2.7M	2.6M	1.6M	564.2K	874K	1.1M	764.2K	535.6K
Accounts Payable	10M	107K	868.1K	970.2K	2.1M	2.1M	1.4M	2.7M	2.6M	1.6M	564.2K	874K	1.1M	764.2K	535.6K
Other Payables	0.0	7.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accrued Expenses	0.0	2.2M	2.3M	4M	6.2M	5.5M	8.7M	6M	5.4M	4.7M	7.2M	5.5M	1M	843.1K	241.7K
Short Term Debt	435K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	0.0	741.6K	918.6K	1M	898.5K	804.1K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	4.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	68.6K	0.0	0.0	0.0	4M	15M
Other Current Liabilities	21.5M	76K	3M	3M	2.5M	3.9M	0.0	98.8K	78K	68.6K	0.0	97K	104.2K	91.6K	584.9K
Total Current Liabilities	36.1M	9.6M	6.8M	8.9M	11.8M	12.4M	11M	8.8M	8.2M	6.3M	7.7M	6.5M	2.3M	5.7M	16.4M
NON-CURRENT LIABILITIES
Long Term Debt	1.2M	37.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.8M
Other Non-Current Liabilities	0.0	4M	0.0	0.0	0.0	264.3K	0.0	611.6K	707K	753.6K	243.6K	0.0	96.8K	199.8K	0.0
Total Non-Current Liabilities	1.2M	41.5M	66.8K	0.0	918.6K	2.2M	2.8M	611.6K	707K	753.6K	243.6K	0.0	96.8K	199.8K	4M
Other Liabilities	0.0	0.0	0.0	0.0	0.0	0.0	-92.0	223.0	0.0	-196.0	-625.0	0.0	0.0	0.0	0.0
Capital Lease Obligations	0.0	0.0	808.4K	918.6K	1.9M	2.8M	3.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	37.3M	51.1M	6.9M	8.9M	12.7M	14.6M	13.8M	9.4M	8.9M	7.1M	8M	6.5M	2.4M	5.9M	20.5M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	346.0	0.0	30.7K	30.7K	30.7K
Common Stock	28K	1K	64.4K	54.4K	52.3K	49K	43.5K	43.2K	34.4K	23.2K	19K	18.9K	1.4K	10.2K	930.0
Additional Paid-In Capital	0.0	2.4M	494.8M	462.5M	454.4M	437.6M	412.6M	406M	271.9M	154.3M	127.6M	125.2M	66.2M	65.2M	64.8M
Retained Earnings	-171.8M	-17.9M	-456.5M	-419.6M	-372.9M	-309.5M	-258.4M	-200.6M	-152.3M	-119M	-87.2M	-74.4M	-63.3M	-52.7M	-56.3M
Accumulated Other Comprehensive Income/Loss	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.6M	-1.3M	-1.1M	-902.1K	-905.5K	-755.9K	-796.2K	-696.3K
Other Total Stockholders' Equity	374.8M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Stockholders' Equity	203M	-15.5M	38.4M	42.9M	81.6M	128.2M	154.2M	205.5M	119.7M	35.3M	40.5M	50.8M	2.9M	12.5M	8.5M
Total Equity	203M	-15.5M	38.4M	42.9M	81.6M	128.2M	154.2M	205.5M	119.7M	35.3M	40.5M	50.8M	2.9M	12.5M	8.5M
SUMMARY
Total Liabilities & Equity	240.3M	35.6M	45.3M	51.8M	94.3M	142.8M	168M	214.8M	128.6M	42.4M	48.5M	57.3M	5.3M	18.4M	28.9M
Total Investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.6K	9.3K	16.3K	1K	0.0	0.0
Total Debt	1.6M	37.5M	808.4K	918.6K	1.9M	2.8M	3.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net Debt	-211.5M	2.7M	-41M	-47M	-88.3M	-134.2M	-154.6M	-209.9M	-123.9M	-40M	-46.8M	-55.2M	-2.3M	-17.4M	-28.2M
Shares Outstanding	13,892,562	13,892,562	13,892,562	13,892,562	13,892,562	13,892,562	13,892,562	13,892,562	13,892,562	13,892,562	13,892,562	13,892,562	13,892,562	13,892,562	13,892,562

SEC Filings

CBIO - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	June 03, 2026	June 02, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 29, 2026	April 29, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	April 29, 2026	March 31, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 21, 2026	June 02, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 26, 2026	February 26, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 26, 2026	December 31, 2025	2025	View Filing
S-1 S-1 N/A	January 07, 2026	January 07, 2026		View Filing
8-K 8-K 2025 N/A	December 04, 2025	December 02, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 06, 2025	November 06, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 06, 2025	September 30, 2025	2025	View Filing

Showing 1 to 10 of 184 filings

Related Guides

Blog Categories

Continue your CBIO research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.